Table 1.
Patient demographic and tumor characteristics
| No. of Patients | 62 |
|---|---|
| Gender, n (%) | |
| Male | 51 (82.3%) |
| Female | 11 (17.7%) |
| Median Age (range) | 68 (38 – 86) |
| Race, n (%) | |
| Caucasians | 59 (95.2%) |
| African Americans | 1 (1.6%) |
| Hispanics | 1 (1.6%) |
| Asians | 1 (1.6%) |
| Histology, n (%) | |
| Adenocarcinoma | 47 (75.8%) |
| Squamous Cell Carcinoma | 14 (22.6%) |
| Mixed Adeno, neuroendocrine | 1 (1.6%) |
| Stage, n (%) | |
| I | 2 (3.2%) |
| II | 20 (32.3%) |
| III | 32 (51.6%) |
| IVa | 2 (3.2%) |
| IVb | 6 (9.7%) |
| Tumor Location, n (%) | |
| Upper | 3 (4.8%) |
| Mid | 11 (17.7%) |
| Distal/GEJ | 48 (77.5%) |
| Treatment, n (%) | |
| Definitive | 33 (53.2%) |
| Neoadjuvant + Surgery | 29 (46.8%) |
| Induction Chemotherapy, n (%) | |
| Yes | 26 (41.9%) |
| No | 36 (58.1%) |
| Median Proton Dose in Gy(RBE) (range) | 50.4 (36 – 57.6) |
Abbreviations: RBE: Relative Biologic Equivalence